局限期或局部晚期前列腺癌的初始管理策略对转移性去势抵抗性前列腺癌的治疗具有关键指导意义
多中心队列纳入2011年7月至2021年10月间开始雄激素受体信号抑制剂(ARSI)治疗的919例转移性去势抵抗性前列腺癌(mCRPC)患者,中位年龄77岁,中位随访91个月。原发进展者中,局限期/局部晚期且激素敏感期雄激素剥夺治疗(ADT)短程(<24个月)者较长程(≥24个月)者总生存更差(局限期短程HR=2.01,局部晚期短程HR=1.73,p<0.001)。作者认为初始管理可能影响mCRPC预后,需前瞻性试验验证。
要点
- mCRPC开始ARSI治疗时,中位总生存20个月,中位无进展生存10个月。
- 原发进展者中,局限期短程ADT较局限期长程ADT死亡风险更高(HR=2.01,95%CI 1.54-2.64,p<0.001)。
- 局部晚期短程ADT较局部晚期长程ADT死亡风险更高(HR=1.73,95%CI 1.34-2.24,p<0.001)。
核心结论
- 激素敏感期ADT持续时间与接受ARSI治疗的mCRPC患者生存显著相关。
- 这些发现提示前列腺肿瘤的初始管理可能与mCRPC更好的预后判断存在关联。
- 作者认为需要前瞻性试验验证。
研究设计与样本
- 多中心队列研究,纳入2011年7月至2021年10月间开始ARSI治疗的mCRPC患者919例。
- 中位年龄77岁(四分位距71-82岁),激素敏感期ADT中位持续时间24个月(四分位距14-40个月)。
- 中位随访91个月(四分位距62-138个月)。
主要发现
- 从开始ARSI起,中位总生存20个月(四分位距10-32个月),中位无进展生存10个月(四分位距5-19个月)。
- 原发进展并发生转移者655例(71.3%),局限期短程ADT组较局限期长程ADT组死亡风险更高(HR=2.01,95%CI 1.54-2.64,p<0.001),局部晚期短程ADT组较局部晚期长程ADT组死亡风险更高(HR=1.73,95%CI 1.34-2.24,p<0.001)。
- 多因素分析(纳入年龄、预后队列、Gleason评分、ECOG评分、根治性放疗和前列腺切除术)中,短程ADT组较长程ADT组总生存更差(局限期:HR=1.84,95%CI 1.38-2.45,p<0.001;局部晚期:HR=1.59,95%CI 1.21-2.10,p<0.001),ECOG>2亦与更差总生存相关(HR=1.55,95%CI 1.06-2.26,p=0.03)。
- 无进展生存结果与总生存结果相似。
- 有原发转移性激素敏感性前列腺癌病史者264例(28.7%),其进展至去势抵抗时间长者总生存更好(HR=0.76,95%CI 0.56-1.02,p=0.064),无进展生存也更好(HR=0.74,95%CI 0.55-0.99,p=0.042)。
临床怎么用
- 原文结论指出,激素敏感期ADT持续时间与接受ARSI治疗的mCRPC患者生存显著相关。
- 作者认为这些发现提示前列腺肿瘤初始管理可能与mCRPC更好的预后判断存在关联。
- 作者认为需要前瞻性试验验证。
局限性
- 作者认为需要前瞻性试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Currently, several therapies are available for metastatic castration-resistant prostate cancer (mCRPC) but no specific clinical factors to personalize treatment. We first sought the prognostic value of duration on androgen-deprivation therapy (ADT) for hormone-sensitive prostate cancer (HSPC) in patients receiving androgen-receptor-signaling inhibitors (ARSI) for mCRPC. METHODS: A multicenter cohort of mCRPC patients who started ARSI between July 2011 and October 2021 was identified. Based on their initial disease burden and duration on ADT for HSPC, primary progressive (PP) men were classified into four groups: low/intermediate-risk localized disease (LOC) and high-risk localized/locally advanced disease (LAD) and short-term (ST) < 24 vs. long-term (LT) ADT ≥ 24 months, whereas de novo (DN) mHSPC were subdivided into short-time vs. long-time to CRPC. RESULTS: We included 919 mCRPC patients with a median age of 77 years [interquartile range (IQR) = 71-82)]. Median ADT duration in HSPC was 24 months (IQR = 14-40). Median follow-up was 91 months (IQR = 62-138), median OS and PFS from ARSI start were 20 (IQR 10-32) and 10 months (IQR = 5-19), respectively. In PP developing metastatic disease (n = 655, 71.3%), LOC and LAD with ST ADT had a greater than almost double-risk of death compared to LT ADT (LOC/ST: hazard ratio [HR] = 2.01; 95% CI 1.54-2.64; LAD/ST: HR = 1.73; 95% CI 1.34-2.24; p < 0.001). In the multivariate analysis including age, prognostic cohort, Gleason, ECOG, radical radiotherapy and prostatectomy, groups with ST ADT were associated with worse OS compared to LT ADT (LOC/ST: HR = 1.84; 95% CI 1.38-2.45; p < 0.001; LAD/ST: HR = 1.59; 95% CI 1.21-2.10; p < 0.001), along with ECOG > 2 (HR = 1.55; 95% CI 1.06-2.26; p = 0.03). There were also similar results of PFS. Moreover, long-time to CRPC in patients with history of DN mHSPC (n = 264, 28.7%) resulted in a better OS/PFS (HR = 0.76, 95% CI 0.56-1.02, p = 0.064 and HR = 0.74, 95% CI 0.55-0.99, p = 0.042, respectively). CONCLUSIONS: Our study showed that duration on ADT for mHSPC was significantly associated with survival in mCRPC undergoing ARSI. These findings suggest a possible connection between initial management of prostate tumour and a better prognostication in mCRPC. Prospective trials are warranted.
引用
- Conteduca V, Di Tullio P, Allamprese R, et al. Initial management approach for localized/locally advanced disease is critical to guide metastatic castration-resistant prostate cancer care. Prostate Cancer Prostatic Dis. 2024. PMID: 38347113. doi:10.1038/s41391-024-00800-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。